Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...
The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...
Obesity is a major global health issue, increasing the risk of heart disease, diabetes, and high blood pressure. Despite many ...
New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...
Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
A next-generation Novo Nordisk metabolic disorder drug led to statistically significant weight loss in a pivotal test in participants with obesity and type 2 diabetes, results it says support ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results